Clinical Trial Update: Add Glucokinase Activator to Target A1c [Phase 2]

View source ↗

Summary

Phase 2 study update on vTv Therapeutics' glucokinase activator TTP399 aimed at lowering HbA1c in type 2 diabetes; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TTP399 (glucokinase activator)

Snippet

Sponsor: vTv Therapeutics | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED